Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 17-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...
GENEVA, SWITZERLAND / ACCESSWIRE / November 7, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, ...
Relief Therapeutics (OTCQB:RLFTF)(OTCQB:RLFTD) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil). The company said the data showed high ...
GENEVA, SWITZERLAND / ACCESSWIRE / September 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF) ("Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief ...
Relief Therapeutics Holding AG and NeuroRx, Inc. announced that they have met the 165 patient enrollment target agreed with the US Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of ...
GENEVA, SWITZERLAND / ACCESSWIRE / April 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to ...
RLF-100 ® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, which was first discovered in 1970. Although initially identified in the intestinal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback